- Home
- DRVN vs CGON Comparison
DRVN vs CGON Comparison
Compare DRVN & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRVN
- CGON
- Stock Information
- Founded
- DRVN 1972
- CGON 2010
- Country
- DRVN United States
- CGON United States
- Employees
- DRVN N/A
- CGON N/A
- Industry
- DRVN Automotive Aftermarket
- CGON
- Sector
- DRVN Consumer Discretionary
- CGON
- Exchange
- DRVN Nasdaq
- CGON NYSE
- Market Cap
- DRVN 2.7B
- CGON 2.2B
- IPO Year
- DRVN 2021
- CGON 2024
- Fundamental
- Price
- DRVN $16.10
- CGON $32.34
- Analyst Decision
- DRVN Buy
- CGON Strong Buy
- Analyst Count
- DRVN 12
- CGON 8
- Target Price
- DRVN $17.88
- CGON $63.88
- AVG Volume (30 Days)
- DRVN 702.0K
- CGON 418.0K
- Earning Date
- DRVN 10-31-2024
- CGON 11-12-2024
- Dividend Yield
- DRVN N/A
- CGON N/A
- EPS Growth
- DRVN N/A
- CGON N/A
- EPS
- DRVN 0.03
- CGON N/A
- Revenue
- DRVN $2,329,148,000.00
- CGON $684,000.00
- Revenue This Year
- DRVN $4.04
- CGON $411.76
- Revenue Next Year
- DRVN $7.93
- CGON $405.27
- P/E Ratio
- DRVN $539.81
- CGON N/A
- Revenue Growth
- DRVN 1.71
- CGON 258.12
- 52 Week Low
- DRVN $10.59
- CGON $25.77
- 52 Week High
- DRVN $16.93
- CGON $50.23
- Technical
- Relative Strength Index (RSI)
- DRVN 57.69
- CGON 34.54
- Support Level
- DRVN $16.41
- CGON $32.53
- Resistance Level
- DRVN $16.79
- CGON $40.47
- Average True Range (ATR)
- DRVN 0.42
- CGON 1.92
- MACD
- DRVN -0.04
- CGON -0.62
- Stochastic Oscillator
- DRVN 61.75
- CGON 11.53
About DRVN Driven Brands Holdings Inc.
Driven Brands Holdings Inc is an automotive services company in North America. Its platform provides high-quality services to an extensive range of retail and commercial customers. The company provides an extensive range of core consumer and commercial automotive needs, including paint, collision, glass, and repair services, as well as a variety of high-frequency services, such as oil changes and car washes.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.